Immunovia AB
OTC: IMMVF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Jeff Borcherding
- Employees
- 13
- Headquarters
- Lund, Sweden
- IPO year
- 2019
- Market cap
- $6.1M
- Website
- https://www.immunovia.com
Loading IMMVF…
Loading profile data…Frequently asked questions about IMMVF
What does Immunovia AB (IMMVF) do?
Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. Its technology platform, IMMray, focuses on the early diagnosis of cancer, predicts disease progression, and monitors therapeutic responsiveness of cancers. The company was founded by Karl Arne Krister Borrebaeck on May 24, 2007 and...
Where does IMMVF trade?
Immunovia AB (IMMVF) trades on the Other OTC.
What sector is IMMVF in?
Immunovia AB (IMMVF) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Immunovia AB?
Jeff Borcherding is the chief executive officer of Immunovia AB (IMMVF).
Where is Immunovia AB headquartered?
Immunovia AB is headquartered in Sweden.
Does IMMVF pay a dividend?
Immunovia AB (IMMVF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMMVF go public?
Immunovia AB (IMMVF) completed its initial public offering in 2019.